News Daily News NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes L.A. McKeown May 03, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
Presentation ACC 2022 Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial Presenter: Duk-Woo Park April 04, 2022
News Conference News TCT 2021 Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter? Todd Neale November 06, 2021
News Conference News ESC 2021 Amulet IDE: LAA Occluder Performs Well Against Watchman Todd Neale August 30, 2021
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021
News Conference News TVT 2021 New-Generation Watchman FLX Maintains Good Results Through 2 Years Todd Neale July 28, 2021
News Conference News ACC 2021 ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI Yael L. Maxwell May 15, 2021
News Daily News New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research Michael O'Riordan April 23, 2021
News Conference News PCR London Valves 2020 No Angina? No Benefit to PCI Pre-TAVR: ACTIVATION Shelley Wood November 26, 2020